The IPTi Consortium: research for policy and action

Trends in Parasitology

Volumn 22, Issue 7, 2006, Pages 296-300

  Schellenberg, David ^a,b   Cisse, Badara ^c   Menendez, Clara ^d  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b IFAKARA HEALTH INSTITUTE   (Tanzania)

^c UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^d CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTESUNATE; CHLORPROGUANIL PLUS DAPSONE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FANSIDAR; MEFLOQUINE;

ENDEMIC DISEASE; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; IMMUNIZATION; MALARIA; MALARIA CONTROL; MEASLES; PREVENTIVE MEDICINE; REVIEW; TANZANIA; UNITED NATIONS; WORLD HEALTH ORGANIZATION;

ANTIMALARIALS; CHILD, PRESCHOOL; HUMANS; INFANT; INTERNATIONAL COOPERATION; MALARIA; POLICY MAKING; RESEARCH; SEASONS; TANZANIA; WORLD HEALTH;

EID: 33745651114     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2006.05.006     Document Type: Review

References (15)

1. Roll Back Malaria (2005) In World Malaria Report. WHO/HTM/MAL/2005.1102, pp. 14-15 (http://www.who.int)
2. Geerligs P.D., et al. Analysis of the effects of malaria chemoprophylaxis in children on haematological responses, morbidity and mortality. Bull. WHO 81 (2003) 205-216
3. Pringle G., and Avery-Jones S. Observations on the early course of untreated falciparum malaria in semi-immune African children following a short period of protection. Bull. WHO 34 (1966) 269-272
4. Menendez C., et al. Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Lancet 350 (1997) 844-850
5. Hogh B., et al. The influence of Maloprim chemoprophylaxis on cellular and humoral immune responses to Plasmodium falciparum asexual blood stage antigens in schoolchildren living in a malaria endemic area of Mozambique. Acta Trop. 57 (1994) 265-277
6. Schellenberg D., et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 357 (2001) 1471-1477
7. WHO (2004) A strategic framework for malaria prevention and control during pregnancy in the African Region. Brazzaville: WHO Regional Office for Africa. AFR/MAL/04/01, pp. 10-12 (http://www.who.int)
8. Egan A., et al. Intermittent preventive treatment for malaria control in infants: moving towards evidence-based policy and public health action. Trop. Med. Int. Health 10 (2005) 815-817
9. Schellenberg D., et al. Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 365 (2005) 1481-1483
10. Massaga J., et al. Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo controlled trial. Lancet 361 (2003) 1853-1860
11. Chandramohan D., et al. A cluster randomised trial of intermittent preventive treatment for malaria in infants in an area of high, seasonal transmission in Ghana. Brit. Med. J. 331 (2005) 727-733
12. Macete, E. et al. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: randomised placebo-controlled trial. J. Infect. Dis. (in press)
13. Schellenberg D., et al. The changing epidemiology of malaria in Ifakara town, southern Tanzania. Trop. Med. Int. Health 9 (2004) 68-76
14. Dicko S., et al. Impact of intermittent preventive treatment with sulfadoxine pyrimethamine targeting the transmission season on the incidence of clinical malaria in children aged 6 months to 10 years in Kambila, Mali. 53rd Annual Meeting of the American Society of Tropical Medicine and Hygiene. Am. J. Trop. Med. Hyg. Suppl. 17 (2004) 6
15. Cisse B., et al. Seasonal intermittent preventive treatment (IPT) with artesunate plus sulfadoxine pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial. Lancet 367 (2006) 659-667